{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:43:39Z","timestamp":1768077819876,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Structure"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.molstruc.2021.131106","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T04:50:26Z","timestamp":1626411026000},"page":"131106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012\/01 strain"],"prefix":"10.1016","volume":"1246","author":[{"given":"Amgad M.","family":"Rabie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molstruc.2021.131106_bib0001","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health \u2014 The latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.molstruc.2021.131106_bib0002","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.micinf.2020.02.002","article-title":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future","volume":"22","author":"Li","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.molstruc.2021.131106_bib0003","unstructured":"COVID-19 Map, available from Johns Hopkins Coronavirus Research Center, accessed in July 5th (2021). https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"10.1016\/j.molstruc.2021.131106_bib0004","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/22221751.2020.1723441","article-title":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies","volume":"9","author":"Jiang","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.molstruc.2021.131106_bib0005","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1007\/s11696-021-01640-9","article-title":"Discovery of (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug","volume":"75","author":"Rabie","year":"2021","journal-title":"Chem. Pap."},{"key":"10.1016\/j.molstruc.2021.131106_bib0006","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1039\/D0NJ03708G","article-title":"Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs","volume":"45","author":"Rabie","year":"2021","journal-title":"New J. Chem."},{"key":"10.1016\/j.molstruc.2021.131106_bib0007","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molstruc.2021.131106_bib0008","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.3595","article-title":"Overcoming drug development bottlenecks with repurposing: Old drugs learn new tricks","volume":"20","author":"Strittmatter","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.molstruc.2021.131106_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.molstruc.2021.131106_bib0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discoveries Ther."},{"key":"10.1016\/j.molstruc.2021.131106_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.molstruc.2021.131106_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.molstruc.2021.131106_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.molstruc.2021.131106_bib0014","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.molstruc.2021.131106_bib0015","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.molstruc.2021.131106_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.molstruc.2021.131106_bib0017","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: An open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.molstruc.2021.131106_bib0018","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","volume":"108","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.molstruc.2021.131106_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molstruc.2021.131106_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109815","article-title":"Does zinc supplementation enhance the clinical efficacy of chloroquine\/hydroxychloroquine to win today's battle against COVID-19?","volume":"142","author":"Derwand","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.molstruc.2021.131106_bib0021","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.molstruc.2021.131106_bib0022","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.molstruc.2021.131106_bib0023","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5923\/j.ajoc.20160602.02","article-title":"Design, synthesis, and biological evaluation of novel 5-substituted-2-(3,4,5-trihydroxyphenyl)-1,3,4-oxadiazoles as potent antioxidants","volume":"6","author":"Rabie","year":"2016","journal-title":"Am. J. Org. Chem."},{"key":"10.1016\/j.molstruc.2021.131106_bib0024","first-page":"21","article-title":"Design, synthesis, and biological evaluation of new 5-substituted-1,3,4-thiadiazole-2-thiols as potent antioxidants","volume":"10","author":"Rabie","year":"2018","journal-title":"Researcher"},{"key":"10.1016\/j.molstruc.2021.131106_bib0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cofs.2020.08.004","article-title":"Potential use of polyphenols in the battle against COVID-19","volume":"32","author":"Paraiso","year":"2020","journal-title":"Curr. Opin. Food Sci."},{"key":"10.1016\/j.molstruc.2021.131106_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109211","article-title":"Roles of flavonoids against coronavirus infection","volume":"328","author":"Russo","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.molstruc.2021.131106_bib0027","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.sjbs.2020.10.028","article-title":"Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study","volume":"28","author":"Rameshkumar","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.molstruc.2021.131106_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2020.107351","article-title":"Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design","volume":"88","author":"Meyer-Almes","year":"2020","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.molstruc.2021.131106_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153311","article-title":"Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic","volume":"85","author":"Khalifa","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.molstruc.2021.131106_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112653","article-title":"Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses","volume":"203","author":"Nebigil","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.molstruc.2021.131106_bib0031","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.aimed.2020.07.007","article-title":"The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review","volume":"7","author":"Aucoin","year":"2020","journal-title":"Adv. Integr. Med."},{"key":"10.1016\/j.molstruc.2021.131106_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001176","article-title":"Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture","volume":"6","author":"te Velthuis","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molstruc.2021.131106_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molstruc.2021.131106_bib0034","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.molstruc.2021.131106_bib0035","unstructured":"COVID-19 Docking Server, accessed in April 10-20th (2021). http:\/\/ncov.schanglab.org.cn."},{"key":"10.1016\/j.molstruc.2021.131106_sbref0036","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.molstruc.2021.131106_bib0037","unstructured":"PatchDock Server, accessed in April 10-20th (2021). https:\/\/bioinfo3d.cs.tau.ac.il\/PatchDock."},{"issue":"Web Server issue","key":"10.1016\/j.molstruc.2021.131106_bib0038","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gki481","article-title":"PatchDock and SymmDock: servers for rigid and symmetric docking","volume":"33","author":"Schneidman-Duhovny","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molstruc.2021.131106_bib0039","unstructured":"FireDock Server, accessed in April 10-20th (2021). http:\/\/bioinfo3d.cs.tau.ac.il\/FireDock."},{"key":"10.1016\/j.molstruc.2021.131106_bib0040","unstructured":"Protein-Ligand Interaction Profiler (PLIP), accessed in April 14-24th (2021). https:\/\/projects.biotec.tu-dresden.de\/plip-web."},{"issue":"Web Server issue","key":"10.1016\/j.molstruc.2021.131106_bib0041","doi-asserted-by":"crossref","first-page":"W443","DOI":"10.1093\/nar\/gkv315","article-title":"PLIP: fully automated protein-ligand interaction profiler","volume":"43","author":"Salentin","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molstruc.2021.131106_bib0042","unstructured":"ProTox-II Virtual Laboratory, accessed in April 14-24th (2021). https:\/\/tox-new.charite.de\/protox_II."},{"issue":"Web Server issue","key":"10.1016\/j.molstruc.2021.131106_bib0043","doi-asserted-by":"crossref","first-page":"W257","DOI":"10.1093\/nar\/gky318","article-title":"ProTox-II: a webserver for the prediction of toxicity of chemicals","volume":"46","author":"Banerjee","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"Web Server issue","key":"10.1016\/j.molstruc.2021.131106_bib0044","doi-asserted-by":"crossref","first-page":"W53","DOI":"10.1093\/nar\/gku401","article-title":"ProTox: a web server for the in silico prediction of rodent oral toxicity","volume":"42","author":"Drwal","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molstruc.2021.131106_bib0045","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/clinchem\/hvaa029","article-title":"Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia","volume":"66","author":"Chu","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.molstruc.2021.131106_bib0046","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.molstruc.2021.131106_bib0047","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molstruc.2021.131106_bib0048","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/microorganisms8101610","article-title":"Detailed molecular interactions of favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus polymerases in silico","volume":"8","author":"Sada","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.molstruc.2021.131106_bib0049","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.3390\/molecules25235695","article-title":"Targeting the RdRp of emerging RNA viruses: The structure-based drug design challenge","volume":"25","author":"Picarazzi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.molstruc.2021.131106_bib0050","doi-asserted-by":"crossref","first-page":"m4857","DOI":"10.1136\/bmj.m4857","article-title":"Covid-19: New coronavirus variant is identified in UK","volume":"371","author":"Wise","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.molstruc.2021.131106_bib0051","doi-asserted-by":"crossref","unstructured":"B. Korber, W.M. Fischer, S. Gnanakaran, H. Yoon, J. Theiler, W. Abfalterer, N. Hengartner, E.E. Giorgi, T. Bhattacharya, B. Foley, K.M. Hastie, M.D. Parker, D.G. Partridge, C.M. Evans, T.M. Freeman, T.I. de Silva, Sheffield COVID-19 Genomics Group; C. McDanal, L.G. Perez, H. Tang, A. Moon-Walker, S.P. Whelan, C.C. LaBranche, E.O. Saphire, D.C. Montefiori, Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus, Cell 182 (2020) 812\u2013827.e19, doi:10.1016\/j.cell.2020.06.043.","DOI":"10.1016\/j.cell.2020.06.043"},{"key":"10.1016\/j.molstruc.2021.131106_bib0052","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","article-title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies","volume":"17","author":"Yi","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.molstruc.2021.131106_bib0053","unstructured":"\"Expert reaction to South African variant of SARS-CoV-2, as mentioned by Matt Hancock at the Downing Street press briefing\", Science Media Centre, 23 December 2020, retrieved in 24 December (2020). The South African variant \u2018501.V2\u2019 is characterised by N501Y, E484K and K417N mutations in the S protein \u2013 so it shares the N501Y mutation with the UK variant, but the other two mutations are not found in the UK variant. Similarly, the South African variant does not contain the 69-70del mutation that is found in the UK variant. https:\/\/www.sciencemediacentre.org\/expert-reaction-to-south-african-variant-of-sars-cov-2-as-mentioned-by-matt-hancock-at-the-downing-street-press-briefing."},{"key":"10.1016\/j.molstruc.2021.131106_bib0054","unstructured":"Explainer: What we know about the Indian variant as coronavirus sweeps South Asia, Reuters, accessed in May 5th (2021). https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/what-we-know-about-indian-variant-coronavirus-sweeps-south-asia-2021-04-30."},{"key":"10.1016\/j.molstruc.2021.131106_bib0055","unstructured":"SARS-CoV-2 Variant Classifications and Definitions, National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases, accessed in May 5th (2021). https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/variant-surveillance\/variant-info.html."}],"container-title":["Journal of Molecular Structure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022286021012370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022286021012370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T06:55:28Z","timestamp":1762671328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022286021012370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":55,"alternative-id":["S0022286021012370"],"URL":"https:\/\/doi.org\/10.1016\/j.molstruc.2021.131106","relation":{},"ISSN":["0022-2860"],"issn-type":[{"value":"0022-2860","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012\/01 strain","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Structure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molstruc.2021.131106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131106"}}